1 Interpharma. http://www.interpharma.ch/fakten-statistiken/1815-herz-kreislauf-erkrankungen-als-haeufigste-diagnose
2 Bundesamt für Gesundheit. Nationale Präventionsprogramme – Studie präsentiert erstmalige Berechnungen der direkten und indirekten Kosten der wichtigsten nichtübertragbaren Krankheiten. Bulletin 14. September 2014.
3 Bundesamt für Statistik. Gesundheitsstatistik 2014. Neuchâtel 2014.
4 Schweizerische Herzstiftung. Zahlen und Daten über Herz-Kreislauf-Krankheiten in der Schweiz.Bern 2012.
5 Miserez AR, Keller U. Prävention der koronaren Herzkrankheit bei familiären Hypercholesterinämien. Ther Umsch. 1994;51:671–6.
6 Miserez AR, et al. High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res. 1994;35(4):574–83.
7 Miserez AR, et al. Polymorphic haplotypes and recombination rates at the LDL receptor gene locus in subjects with and without familial hypercholesterolemia who are from different populations. Am J Hum Genet. 1993;52(4):808–26.
8 Goldberg AC, et al. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. J Clin Lipidol. 2011;5(3):S1–S8.
9 Pearson TA, et al. The lipid treatment assessment project (l-tap): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459–67.
10 Mancini GBJ, et al. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. Can J Cardiol. 2011;29(12):1553–68.
11 Baigent C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
12 Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–97.
13 Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J. 2013;34(24):1783–9.
14 Mullard A. Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat Rev Drug Discov. 2012;11(11):817–9.
15 Robinson JG, et al, Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on ldl-c lowering in patients with hypercholesterolemia: The laplace-2 randomized clinical trial. JAMA. 2014;311(18):1870–83.
16 Nicholls SJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: The glagov randomized clinical trial. JAMA. 2016; 316 (22): 2372-2384.
17 Puri R, et al, Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016;176:83–92.
18 Zhang H, et al. Discontinuation of Statins in Routine Care SettingsA Cohort Study. Ann Intern Med. 2013;158(7):526–34.
19 Stroes E, et al. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance: The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab. J Am Coll Cardiol. 2014;63(23):2541–8.
20 Koren MJ, et al. Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab. J Am Coll Cardiol. 2014;63(23):2531–40.
21 Raal FJ, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet. 2014;385(9965):331–40.
22 Marais AD, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008;197(1):400–6.
23 Raal FJ, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997;135(2):249–56.
24 Gagné C, et al, Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia. Circulation. 2002;105(21):2469–75.
25 Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–90a.
26 Raal FJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet. 2014;385(9965):341–50.
27 Pedro-Botet J, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158(1):183–93.
28 Sabatine MS, et al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015;372(16):1500–9.
29 Blom DJ, et al. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. N Engl J Med. 2014;370(19):1809–19.
30 Bays H, et al. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab. 2015;100(8):3140–8.
31 Cannon CP, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186–94.
32 Farnier M, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138–46.
33 Ginsberg HN, et al. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016;30(5):473–83.
34 Kastelein JJP, et al, ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996–3003.
35 Kereiakes DJ, et al, Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906–915.e13.
36 Moriarty PM, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6): 758–69.
37 Robinson JG, et al, Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015;372(16):1489–1499.
38 Roth EM, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014;176(1):55–61.
39 Schwartz GG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. Am Heart J. 2014;168(5):682–9.e1.
40 Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11(10):563–75.
41 Ballantyne CM, et al. Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia. Am J Cardiol. 2015;115(9):1212–21.
42 ClinicalTrials.gov, Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-HR). http://ClinicalTrials.gov/show/NCT01968954, NCT01968954.
43 ClinicalTrials.gov, Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL). http://ClinicalTrials.gov/show/NCT01968967, NCT01968967.
44 ClinicalTrials.gov, A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (SPIRE-FH). http://ClinicalTrials.gov/show/NCT01968980, NCT01968980.
45 ClinicalTrials.gov, The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1). http://ClinicalTrials.gov/show/NCT01975376, NCT01975376.
46 ClinicalTrials.gov, The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). http://ClinicalTrials.gov/show/NCT01975389, NCT01975389.
47 Pfizer, Press release: Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor. http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor, 2016.
48 Ridker PM, et al. Cardiovascular efficacy and sfety of bococizumab in high-risk patients. N Engl J Med. 2017; DOI: 10.1056/NEJMoa1701488
49 Cicero AF, Colletti A, Borghi C. Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther, 2015. 9: p. 3073-82.
50 Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017. 10.1056/NEJMoa1615664.
51 Swiger K, S Martin S. PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials. Drug Safety. 2015;38(6):519–26.
52 McFarland A, et al. Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System. Int J Mol Sci. 2014;15(11):20607.
53 ClinicalTrials.gov, Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS). https://clinicaltrials.gov/ct2/show/NCT02207634, NCT02207634.
54 Jones PH, et al. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. Am J Cardiol. 2016;118(12):1805–1811.
55 ClinicalTrials.gov, Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG). https://clinicaltrials.gov/ct2/show/NCT01624142, NCT01624142.
56 Gupta S. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Vasc Health Risk Manag. 2016;12:421–33.
